Matthew Kruger, MD
Ophthalmology · Denver, CONPI 1265603781
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.0% of the total across 198 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 35 manufacturers, the largest accounting for just 23.6% — the pattern of someone who eats at a lot of different presentations.
Across 198 payments — averaging $39.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alcon$2K
- AbbVie$856
- Bausch & Lomb Americas Inc.$552
- Rxsight Inc$496
- Sight Sciences, Inc.$375
- Aerie Pharmaceuticals, Inc.$374
- plus $3K from 29 others
What the payments were for
- Speaking & faculty fees$260%
- Food & beverage$7,56797%
- Education$981%
- Entertainment$1111%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alcon | 37 | $1,841 |
| AbbVie(2 entities) | 38 | $856 |
| Bausch & Lomb Americas Inc. | 5 | $552 |
| Rxsight Inc | 5 | $496 |
| Sight Sciences, Inc. | 11 | $375 |
| Aerie Pharmaceuticals, Inc. | 10 | $374 |
| Mallinckrodt Hospital Products Inc. | 12 | $341 |
| NEW World Medical,inc. | 3 | $335 |
| Johnson & Johnson Surgical Vision, Inc. | 3 | $307 |
| Sun Pharmaceutical Industries Inc. | 8 | $246 |
| Carl Zeiss Meditec USA, Inc. | 1 | $190 |
| Kala Pharmaceuticals, Inc. | 9 | $173 |
| Thea Pharma Inc. | 10 | $158 |
| Microsurgical Technology, Inc. | 1 | $154 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 3 | $135 |
| Avedro Inc. | 1 | $125 |
| Optos, Inc. | 3 | $121 |
| Sanofi | 1 | $114 |
| E.r. Squibb & Sons, L.L.C. | 1 | $108 |
| ABB Con-cise Optical Group LLC | 3 | $102 |
| Tarsus Pharmaceuticals, Inc. | 4 | $95 |
| Novartis | 4 | $85 |
| Akorn Operating Company LLC | 5 | $80 |
| Dompe US, Inc. | 3 | $72 |
| Akorn, Inc. | 4 | $67 |
| Amgen | 2 | $57 |
| Nova Eye, Inc. | 1 | $38 |
| Johnson & Johnson Vision Care, Inc. | 2 | $38 |
| Mallinckrodt Enterprises LLC | 1 | $34 |
| Oyster Point Pharma, Inc. | 1 | $28 |
| Coopervision Inc. | 2 | $28 |
| Biotissue Holdings Inc. | 1 | $23 |
| Abbott | 1 | $22 |
| Harrow Eye, LLC | 1 | $16 |
| Rayner Intraocular Lenses Limited | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- enVista MX60 IOL$387
- Rhopressa$371
- Rocklatan$371
- RXSIGHT CONTACT LENS$315
- RXSIGHT INJECTOR HANDPIECE$315
- LIGHT ADJUSTABLE LENS (LAL)$315
- RXSIGHT INJECTOR CARTRIDGE$315
- RXSIGHT LIGHT DELIVERY DEVICE (LDD)$315
- Unity$271
- DURYSTA$246
- STELLARIS$240
- Clareon$230
- EQ Workplace$190
- Tecnis IOL$187
- IC-8 Apthera IOL$147
- TEARCARE SYSTEM$143
- NGENUITY$140
- Hydrus Microstent$134
- XEN$133
- MIEBO$121
How this compares
$7,801 in reported general payments places this provider in the 85th percentile of 262 ophthalmology providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 68 | $90,649 |
| LumiganBimatoprost | 57 | $32,723 |
| Cyclosporine | 18 | $12,851 |
| XiidraLifitegrast | 14 | $9,666 |
| Fluorometholone | 98 | $7,450 |
| Prednisolone Acetate | 134 | $5,981 |
| Dorzolamide-TimololDorzolamide/Timolol/Pf | 21 | $4,904 |
| Loteprednol Etabonate | 37 | $4,875 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 12 | $4,728 |
| Travoprost | 18 | $4,128 |
| Latanoprost | 329 | $3,802 |
| TafluprostTafluprost/Pf | 15 | $2,629 |
| Brinzolamide | 12 | $1,651 |
| Timolol Maleate | 67 | $1,620 |
| ValacyclovirValacyclovir Hcl | 18 | $1,454 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan | $856 | $123,372125 claims |
| Bausch & Lomb Americas Inc.Xiidra | $552 | $9,66614 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate | $135 | $4,87537 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 262 ophthalmology providers in Colorado.
Other ophthalmology in Denver
- Mark DaceyDenver$370K
- Cristos IfantidesDenver$343K
- Jack ZamoraDenver$172K
- Eva KimDenver$95K
- Michael JansenDenver$95K
- Kingsley OkaforDenver$62K
- Curtis HagedornDenver$25K
- Michael SolomonDenver$12K
- Peter HovlandDenver$10K
- Stuart LewisDenver$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.